Zelandopam

Zelandopam
File:Zelandopam structure.png
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	123456-78-9
PubChem	123456
DrugBank
ChemSpider	123456
KEGG	D12345

Zelandopam is a synthetic compound that acts as a selective dopamine receptor agonist, specifically targeting the D1-like receptor subtypes. It is primarily researched for its potential therapeutic effects in cardiovascular diseases, particularly in managing hypertension and heart failure.

Pharmacology

Zelandopam functions by stimulating the D1-like dopamine receptors, which are G-protein coupled receptors that activate adenylate cyclase, leading to increased levels of cyclic adenosine monophosphate (cAMP) within cells. This cascade results in vasodilation, particularly in the renal and mesenteric vascular beds, which can lead to a reduction in blood pressure and improved renal perfusion.

Mechanism of Action

The primary mechanism of action of Zelandopam involves its agonistic activity at the D1-like receptors. Upon binding to these receptors, Zelandopam induces a conformational change that activates the associated G-protein, stimulating adenylate cyclase. The resultant increase in cAMP levels leads to the relaxation of smooth muscle cells in the vasculature, promoting vasodilation and reducing systemic vascular resistance.

Pharmacokinetics

Zelandopam is administered intravenously due to its poor oral bioavailability. It has a rapid onset of action, with effects observed within minutes of administration. The drug is metabolized primarily in the liver and excreted via the kidneys. The half-life of Zelandopam is relatively short, necessitating continuous infusion for sustained therapeutic effects.

Clinical Applications

Zelandopam has been investigated for its potential use in the treatment of acute hypertensive crisis and congestive heart failure. Its ability to selectively dilate renal blood vessels makes it a candidate for improving renal function in patients with compromised kidney perfusion.

Hypertension

In clinical trials, Zelandopam has demonstrated efficacy in rapidly reducing blood pressure in patients experiencing hypertensive emergencies. Its renal vasodilatory effects also suggest potential benefits in managing chronic hypertension, although further studies are needed to establish long-term safety and efficacy.

Heart Failure

The use of Zelandopam in heart failure is based on its ability to reduce afterload and improve cardiac output by decreasing systemic vascular resistance. However, its role in chronic heart failure management remains investigational.

Adverse Effects

Common adverse effects associated with Zelandopam include headache, dizziness, nausea, and hypotension. Due to its potent vasodilatory effects, careful monitoring of blood pressure is required to avoid excessive hypotension.

Research and Development

Zelandopam is currently under investigation in various clinical trials to better understand its therapeutic potential and safety profile. Ongoing research aims to elucidate its role in renal protection and its long-term effects on cardiovascular health.

Also see

• Dopamine receptor
• Hypertension
• Heart failure
• Vasodilator